The global celfree fetal DNA testing market is expected to grow at a CAGR of 8.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing number of women who are opting for prenatal screening and diagnosis, which in turn will lead to an increase in demand for celfree fetal DNA testing.
The abnormal chromosome number detection segment accounted for the largest share of the global celfree fetal DNA testing market in 2018, followed by gender testing and paternally inherited disorder detection segments. The abnormal chromosome number detection segment is expected to continue its dominance throughout the forecast period due to its wide range of applications such as Down syndrome screening and diagnosis, trisomy 18 screening and diagnosis, Turner syndrome screening and diagnosis, Klinefelter syndrome screening and diagnosis among others.
- The Cell-Free Fetal DNA Testing market is expected to reach USD 1,890 million by 2022.
- Increasing number of pregnant women are opting for prenatal screening tests which will drive the growth of the Cell-Free Fetal DNA Testing market.
- Increasing awareness about prenatal screening tests and its benefits among pregnant women will drive the growth of the Cell-Free Fetal DNA Testing market.
- Growing healthcare expenditure in developing countries such as China and India will fuel the growth of the Cell-Free Fetal DNA Testing market.
Industry Growth Insights published a new data on “Cell-Free Fetal DNA Testing Market”. The research report is titled “Cell-Free Fetal DNA Testing Market research by Types (Abnormal Chromosome Number Detection, Gender Testing, Paternally Inherited Disorder Detection, Paternity testing, Otehrs), By Applications (Hospital, Clinic Center), By Players/Companies Sequenom Laboratories, Illumina, Inc., Ariosa Diagnostics, Arup Laboratories, The Fetal Medicine Centre, Apollo Path labs”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cell-Free Fetal DNA Testing Market Research Report
By Type
Abnormal Chromosome Number Detection, Gender Testing, Paternally Inherited Disorder Detection, Paternity testing, Otehrs
By Application
Hospital, Clinic Center
By Companies
Sequenom Laboratories, Illumina, Inc., Ariosa Diagnostics, Arup Laboratories, The Fetal Medicine Centre, Apollo Path labs
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Cell-Free Fetal DNA Testing Market Report Segments:
The global Cell-Free Fetal DNA Testing market is segmented on the basis of:
Types
Abnormal Chromosome Number Detection, Gender Testing, Paternally Inherited Disorder Detection, Paternity testing, Otehrs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic Center
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sequenom Laboratories
- Illumina, Inc.
- Ariosa Diagnostics
- Arup Laboratories
- The Fetal Medicine Centre
- Apollo Path labs
Highlights of The Cell-Free Fetal DNA Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Abnormal Chromosome Number Detection
- Gender Testing
- Paternally Inherited Disorder Detection
- Paternity testing
- Otehrs
- By Application:
- Hospital
- Clinic Center
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cell-Free Fetal DNA Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cell-free fetal DNA testing is a type of genetic testing that uses a sample of cells from the fetus, rather than the mother's blood or tissue. This type of test can be used to detect certain birth defects or chromosomal abnormalities in the fetus.
Some of the major players in the cell-free fetal dna testing market are Sequenom Laboratories, Illumina, Inc., Ariosa Diagnostics, Arup Laboratories, The Fetal Medicine Centre, Apollo Path labs.
The cell-free fetal dna testing market is expected to register a CAGR of 8.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cell-Free Fetal DNA Testing Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Cell-Free Fetal DNA Testing Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Cell-Free Fetal DNA Testing Market - Supply Chain
4.5. Global Cell-Free Fetal DNA Testing Market Forecast
4.5.1. Cell-Free Fetal DNA Testing Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Cell-Free Fetal DNA Testing Market Size (000 Units) and Y-o-Y Growth
4.5.3. Cell-Free Fetal DNA Testing Market Absolute $ Opportunity
5. Global Cell-Free Fetal DNA Testing Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Type
5.3.1. Abnormal Chromosome Number Detection
5.3.2. Gender Testing
5.3.3. Paternally Inherited Disorder Detection
5.3.4. Paternity testing
5.3.5. Otehrs
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Cell-Free Fetal DNA Testing Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic Center
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Cell-Free Fetal DNA Testing Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Cell-Free Fetal DNA Testing Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Cell-Free Fetal DNA Testing Demand Share Forecast, 2019-2026
9. North America Cell-Free Fetal DNA Testing Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic Center
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Type
9.7.1. Abnormal Chromosome Number Detection
9.7.2. Gender Testing
9.7.3. Paternally Inherited Disorder Detection
9.7.4. Paternity testing
9.7.5. Otehrs
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Cell-Free Fetal DNA Testing Demand Share Forecast, 2019-2026
10. Latin America Cell-Free Fetal DNA Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic Center
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Type
10.7.1. Abnormal Chromosome Number Detection
10.7.2. Gender Testing
10.7.3. Paternally Inherited Disorder Detection
10.7.4. Paternity testing
10.7.5. Otehrs
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Cell-Free Fetal DNA Testing Demand Share Forecast, 2019-2026
11. Europe Cell-Free Fetal DNA Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic Center
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Type
11.7.1. Abnormal Chromosome Number Detection
11.7.2. Gender Testing
11.7.3. Paternally Inherited Disorder Detection
11.7.4. aternity testing
11.7.5. Otehrs
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Cell-Free Fetal DNA Testing Demand Share, 2019-2026
12. Asia Pacific Cell-Free Fetal DNA Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic Center
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Type
12.7.1. Abnormal Chromosome Number Detection
12.7.2. Gender Testing
12.7.3. Paternally Inherited Disorder Detection
12.7.4. Paternity testing
12.7.5. Otehrs
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Cell-Free Fetal DNA Testing Demand Share, 2019-2026
13. Middle East & Africa Cell-Free Fetal DNA Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic Center
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Cell-Free Fetal DNA Testing Market Size and Volume Forecast by Type
13.7.1. Abnormal Chromosome Number Detection
13.7.2. Gender Testing
13.7.3. Paternally Inherited Disorder Detection
13.7.4. Paternity testing
13.7.5. Otehrs
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Cell-Free Fetal DNA Testing Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Cell-Free Fetal DNA Testing Market: Market Share Analysis
14.2. Cell-Free Fetal DNA Testing Distributors and Customers
14.3. Cell-Free Fetal DNA Testing Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sequenom Laboratories
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Illumina, Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Ariosa Diagnostics
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Arup Laboratories
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. The Fetal Medicine Centre
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Apollo Path labs
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
